Higgins D L, Lamb M C, Young S L, Powers D B, Anderson S
Department of Cardiovascular Research, Genentech, Inc., South San Francisco, CA 94080.
Thromb Res. 1990 Feb 15;57(4):527-39. doi: 10.1016/0049-3848(90)90070-s.
Tissue plasminogen activator (t-PA) is homologous to other serine proteases and contains an apparent activation cleavage site at arginine 275. It has been demonstrated that this arginine-275 can be replaced with either glutamic acid (Tate, K. M., Higgins, D. L., Holmes, W. E., Winkler, M. E., Heyneker, H. L., and Vehar, G. A. Biochemistry 26, 338-343, 1987) or glycine (Peterson, L. C., Johannessen, M., Foster, D., Kumar, A., and Mulvihill, E. Biochim. Biophys. Acta 952, 245-254, 1988; Boose, J. A., Kuismanen, E., Gerard, R., Sambrook, J. and Gething, M.-J. Biochemistry 28, 635-643, 1989) so that the product of the plasminogen activation reaction, plasmin, can no longer hydrolyze the one-chain form of t-PA to the two-chain form. These "one-chain" t-PA variants had diminished activity, compared to wild-type t-PA, in the absence of a cofactor, but in the presence of the fibrin(ogen) cofactor the two variants had activity similar to wild-type t-PA. In order to compare the effects of all possible substitutions, t-PA variants with each of the other nineteen amino acids besides arginine at position 275 were produced by site-directed mutagenesis. All were recovered from cell culture supernatants completely in the one-chain form, except for R275 (wild-type) and R275K, which were partially converted to the two-chain form. These latter two species could be completely converted to the two-chain form by plasmin. In addition, these two forms showed significantly more plasminogen activating activity in the absence of a fibrin(ogen) cofactor, compared to the other 18 variants. In the presence of a cofactor, all of the t-PA mutants had plasminogen activating activity equivalent to wild-type t-PA, except for R275C. The R275C t-PA had comparatively less clot lysis and fibrin binding activity as well. Presumably the new cysteine in this variant was involved in a mixed disulfide or caused misfolding of the molecule resulting in decreased activity. The difference in the plasminogen activating activity of one- and two-chain forms of t-PA was investigated by determining the apparent Michaelis constants and the apparent turnover numbers for R275E t-PA, which remains in the one-chain form throughout the assay, and two-chain R275 t-PA. The kinetic constants were measured in both the presence and the absence of plasmin-digested fibrinogen.(ABSTRACT TRUNCATED AT 400 WORDS)
组织型纤溶酶原激活剂(t-PA)与其他丝氨酸蛋白酶同源,在精氨酸275处有一个明显的激活切割位点。已经证明,这个精氨酸275可以被谷氨酸(泰特,K.M.,希金斯,D.L.,霍姆斯,W.E.,温克勒,M.E.,海内克,H.L.和维哈尔,G.A.《生物化学》26,338 - 343,1987)或甘氨酸(彼得森,L.C.,约翰内森,M.,福斯特,D.,库马尔,A.和马尔维希尔,E.《生物化学与生物物理学报》952,245 - 254,1988;布斯,J.A.,库伊斯马宁,E.,杰勒德,R.,桑布鲁克,J.和格辛,M.-J.《生物化学》28,635 - 643,1989)取代,这样纤溶酶原激活反应的产物纤溶酶就不能再将单链形式的t-PA水解为双链形式。与野生型t-PA相比,在没有辅因子的情况下,这些“单链”t-PA变体的活性降低,但在有纤维蛋白(原)辅因子存在时,这两种变体的活性与野生型t-PA相似。为了比较所有可能取代的影响,通过定点诱变产生了除275位精氨酸外的其他19种氨基酸各自取代的t-PA变体。除了R275(野生型)和R275K部分转化为双链形式外,所有变体都以单链形式从细胞培养上清液中完全回收。后两种形式可被纤溶酶完全转化为双链形式。此外,与其他18种变体相比,在没有纤维蛋白(原)辅因子的情况下,这两种形式显示出显著更高的纤溶酶原激活活性。在有辅因子存在时,除了R275C外,所有t-PA突变体的纤溶酶原激活活性与野生型t-PA相当。R275C t-PA的凝块溶解和纤维蛋白结合活性也相对较低。推测该变体中的新半胱氨酸参与了混合二硫键形成或导致分子错误折叠,从而导致活性降低。通过测定R275E t-PA(在整个测定过程中保持单链形式)和双链R275 t-PA的表观米氏常数和表观转换数,研究了t-PA单链和双链形式在纤溶酶原激活活性上的差异。动力学常数在有和没有纤溶酶消化的纤维蛋白原存在的情况下都进行了测量。(摘要截断于400字)